-
公开(公告)号：US08680111B2
公开(公告)日：2014-03-25
申请号：US13786106
申请日：2013-03-05
Applicant: Pfizer Inc.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: A01N43/42 , A61K31/44 , A01N43/02 , A61K31/335 , C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00 , C07D313/00
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20140135339A1
公开(公告)日：2014-05-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/18 , C07D498/22
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
Patent Agency Ranking
公开(公告)号：US09593097B2
公开(公告)日：2017-03-14
申请号：US14968405
申请日：2015-12-14
Applicant: Pfizer Inc.
Inventor： Ted William Johnson , Paul Francis Richardson , Michael Raymond Collins , Daniel Tyler Richter , Benjamin Joseph Burke , Sacha Ninkovic , Ketan Satish Gajiwala , Maria Angelica Linton , Phuong Thi Quy Le , Jacqui Elizabeth Hoffman
IPC: C07D401/14 , C07D403/14 , A61K31/53 , A61K31/506 , A61K31/4523 , A61P35/00 , C07D405/14 , C07D471/04 , C07D487/04
CPC classification number: C07D401/14 , A61K31/4523 , A61K31/506 , A61K31/53 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04
Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。
-
公开(公告)号：US20160176850A1
公开(公告)日：2016-06-23
申请号：US14968405
申请日：2015-12-14
Applicant: Pfizer Inc.
Inventor： Ted William Johnson , Paul Francis Richardson , Michael Raymond Collins , Daniel Tyler Richter , Benjamin Joseph Burke , Sacha Ninkovic , Ketan Satish Gajiwala , Maria Angelica Linton , Phuong Thi Quy Le , Jacqui Elizabeth Hoffman
IPC: C07D401/14 , C07D471/04 , C07D487/04 , C07D405/14
CPC classification number: C07D401/14 , A61K31/4523 , A61K31/506 , A61K31/53 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04
Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。
-
公开(公告)号：US20230157998A1
公开(公告)日：2023-05-25
申请号：US17905686
申请日：2021-03-03
Applicant: Pfizer Inc.
Inventor： Padmavani Bezawada , Benjamin Joseph Burke , Emma Louise Hawking , Robert Louis Hoffman , Robert Steven Kania , Jonathan Richard Lillis , Matthew Nathan O'Brien Laramy , Klimentina Dimitrova Pencheva , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst
IPC: A61K31/405 , A61K31/706 , A61K31/7052 , A61K9/00
CPC classification number: A61K31/405 , A61K31/706 , A61K31/7052 , A61K9/0019
Abstract: The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof. The invention also relates to inhibiting SARS-CoV-2 coronavirus viral replication activity comprising contacting SARS-CoV-2-related coronavirus protease with a therapeutically effective amount of a SARS-Cov-2 protease inhibitor, such as a SARS-Cov-2 3CL protease inhibitor and compositions comprising the same
-
公开(公告)号：US09133215B2
公开(公告)日：2015-09-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07D513/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20130252961A1
公开(公告)日：2013-09-26
申请号：US13786106
申请日：2013-03-05
Applicant: PFIZER INC.
Inventor： Simon BAILEY , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/08 , C07D513/18 , C07D498/22 , C07D498/18 , C07D491/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Phi）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
-
-
-
-
-
Search Results
7
records
(took 0.031 seconds)
